^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
K-NK002
i
Other names: CSTD002-NK, CSTD002, CSTD 002 NK, K-NK002
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sanofi
Drug class:
NK cell stimulant
Related drugs:
over3years
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) (clinicaltrials.gov)
P2, N=0, Withdrawn, Kiadis Pharma | N=63 --> 0 | Active, not recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
FLT3 (Fms-related tyrosine kinase 3) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
FLT3-ITD mutation
|
K-NK002
over3years
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) (clinicaltrials.gov)
P2, N=63, Active, not recruiting, Kiadis Pharma | Not yet recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Nov 2023
Enrollment closed • Trial completion date
|
FLT3 (Fms-related tyrosine kinase 3) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
FLT3-ITD mutation
|
K-NK002
4years
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) (clinicaltrials.gov)
P2, N=63, Not yet recruiting, Kiadis Pharma | Initiation date: Jul 2020 --> Nov 2020
Trial initiation date
|
FLT3 (Fms-related tyrosine kinase 3) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
FLT3-ITD mutation
|
K-NK002
over4years
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) (clinicaltrials.gov)
P2, N=63, Not yet recruiting, Kiadis Pharma
New P2 trial
|
FLT3 (Fms-related tyrosine kinase 3) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
FLT3-ITD mutation
|
K-NK002
Share via
